parp inhibitor - Robuta Search

https://www.benthamscience.com/article/91932 Kinase Phosphorylation-based Mechanisms of PARP Inhibitor Resistance During Synthetic Lethal... Background: Poly-(ADP-Ribose) Polymerase (PARP) plays a central role in recovery from single-strand DNA (ssDNA) damage via base excision repair. When P parp inhibitor kinase phosphorylation based mechanisms https://ecancer.org/en/video/8304-profound-parp-inhibitor-olaparib-compared-with-new-hormonal-agents-in-advanced-castration-resistant-prostate-cancer PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration... Prof Maha Hussain speaks to ecancer at ESMO 2019 in Barcelona about data from the PROfound trial comparing the PARP inhibitor olaparib with new hormonal agen parp inhibitor hormonal agents profound olaparib compared https://www.repository.cam.ac.uk/items/788de607-5de3-4825-b4c6-0d525b46ac6f Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. Due to compromised homologous recombination (HR) repair, BRCA1- and BRCA2-mutated tumours accumulate DNA damage and genomic rearrangements conducive of tumour... parp inhibitor targets deficient tumours resistance https://www.jadpro.com/cme-supplements/volume-8-supplement-3-oct-2017/brca-related-ovarian-cancers-and-the-role-of-parp-inhibitor-therapy/ JADPRO | BRCA-Related Ovarian Cancers and the Role of PARP Inhibitor Therapy role of parp inhibitor brca related ovarian https://www.bopa.org.uk/resources/description-of-a-pharmacist-led-parp-inhibitor-clinic-for-patients-with-ovarian-cancer-in-nova-scotia-canada/ Description of a Pharmacist-led PARP Inhibitor Clinic for Patients with Ovarian Cancer in Nova... You do not have access to this area. Please contact a website administrator if this is incorrect. Login parp inhibitor for patients ovarian cancer description pharmacist https://christie.openrepository.com/entities/publication/0255f1f3-8ea6-4e79-b09c-76463dd7713b A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic... multi centre parp inhibitor phase trial olaparib https://avesis.hacettepe.edu.tr/yayin/df2a4ffb-4e38-4c8d-95eb-09e87f1ec393/outcomes-of-first-line-parp-inhibitor-therapy-in-ovarian-cancer-a-multicenter-retrospective-analysis Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective... first line parp inhibitor ovarian cancer outcomes therapy https://www.canceropole-est.org/la-recherche-au-sein-du-canceropole-est/annuaires/publications-scientifiques/detail/?id=45602 Prevention and management of PARP inhibitor-related haematological toxicities in prostate cancer:... parp inhibitor prostate cancer prevention management related https://www.pharmiweb.com/press-release/2021-05-07/china-nmpa-approves-parp-inhibitor-pamiparib-for-patients-with-previously-treated-advanced-ovarian-c China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian... Pamiparib becomes the first PARP inhibitor approved in both platinum-sensitive and platinum-resistant relapsed ovarian cancer in ChinaThis marks the first... parp inhibitor for patients china nmpa approves https://www.mdanderson.org/newsroom/archived-news/parp-inhibitor-improves-progression-free-survival-in-patients-with-advanced-breast-cancers-and-BRCA-mutations.h00-159150768.html ARCHIVED: PARP inhibitor improves progression-free survival in patients with advanced breast... In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended... parp inhibitor archived improves progression free https://pubmed.ncbi.nlm.nih.gov/20092359/ Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888 Poly-ADP-ribose polymerases (PARPs) catalyze transfer of ADP-ribose from NAD(+) to specific residues in their substrate proteins or to growing ADP-ribose... crystal structure parp inhibitor catalytic domain human https://iris.unito.it/handle/2318/2030911 Homologous Recombination deficiency classification and PARP inhibitor response of reference-free... homologous recombination parp inhibitor deficiency classification response https://www.consultant360.com/exclusive/high-tumor-mutational-burden-may-boost-parp-inhibitor-response-brca-mutant-cancers High Tumor Mutational Burden May Boost PARP Inhibitor Response in BRCA-Mutant Cancers |... A retrospective analysis presented at the American Society of Clinical Oncology 2025 Annual Meeting suggests that higher tumor mutational burden (TMB) may be... parp inhibitor high tumor burden may https://pure.ewha.ac.kr/en/publications/impact-of-parp-inhibitor-maintenance-therapy-in-newly-diagnosed-a/ Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer:... parp inhibitor maintenance therapy newly diagnosed ovarian cancer impact https://hoosiercancer.org/multi-site-phase-ii-study-tests-parp-inhibitor-olaparib-in-metastatic-urothelial-cancer-patients-with-somatic-ddr-alterations/ Multi-site phase II study tests PARP inhibitor olaparib in metastatic urothelial cancer patients... Dec 14, 2024 - A Hoosier Cancer Research Network multi-site phase II study led by Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute is testing the poly... multi site phase ii parp inhibitor urothelial cancer study https://letswinpc.org/research/parp-inhibitor-metastatic-pancreatic-cancer-mutations/ PARP Inhibitor for Metastatic Pancreatic Cancer Mutations - Let's Win Pancreatic Cancer Jan 20, 2023 - Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations. parp inhibitor pancreatic cancer metastatic mutations let https://biotechhunter.com/trials/NCT04999605 NCT04999605 - A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian... View clinical trial NCT04999605 details a study parp inhibitor the treatment combined recurrent https://uthscsa.edu/medicine/news/key-dna-complex-connected-parp-inhibitor-cancer-drug-resistance-discovered Key DNA complex connected to PARP inhibitor cancer-drug resistance discovered | Long School of... Scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have made one of the most important discoveries to date in... parp inhibitor drug resistance long school key dna https://www.aacr.org/patients-caregivers/progress-against-cancer/parp-inhibitor-breast-cancer-talazoparib-talzenna/ New PARP Inhibitor Approved for Breast Cancer | The AACR Dec 28, 2019 - The FDA approved a targeted therapeutic for treating patients with breast cancer that tests positive for a cancer-associated BRCA1 or BRCA2 mutations. parp inhibitor breast cancer new approved aacr https://www.epistemonikos.org/en/documents/28ced3627288a700739c26ebb33666dc68ff41b8 Identification, Monitoring and Reversibility of PARP Inhibitor Associated Clonal Haematopoiesis and... parp inhibitor identification monitoring reversibility associated https://data.mendeley.com/datasets/n9txt6y5cj/1 TRABID deubiquitinase overexpression enables synthetic lethality to PARP inhibitor via prolonged... Here, we demonstrate that TRABID deubiquitinase (DUB) binds to 53BP1 at endogenous level and regulates 53BP1 retention at DSB sites. TRABID deubiquitinates... synthetic lethality parp inhibitor via https://herseninstituut.nl/publicaties/nasp-modulates-histone-turnover-to-drive-parp-inhibitor-resistance/ NASP modulates histone turnover to drive PARP inhibitor resistance - Nederlands Herseninstituut -... parp inhibitor nasp histone turnover drive https://discovery.fiu.edu/display/pub97854 The role of NF-kappa B in PARP-inhibitor-mediated sensitization and detoxification of arsenic... role of parp inhibitor nf kappa mediated https://edrn.cancer.gov/data-and-resources/publications/30967398-2850-nsup6sup-methylation-of-adenosine-of-ifzd10i-mrna-contributes-to-parp-inhibitor-resistance/ Nsup6/sup-Methylation of Adenosine of iFZD10/i mRNA Contributes to PARP Inhibitor... This is a publication by a member of the Early Detection Research Network. parp inhibitor sup methylation adenosine mrna https://bpno.dk/medtalks/optimizing-parp-inhibitor-therapy-for-ovarian-cancer/ Optimizing PARP Inhibitor Therapy for Ovarian Cancer Aug 7, 2024 - Join Mansoor Raza Mirza as he delves into the field of second-line PARP inhibitor therapy in ovarian cancer. In this MEDtalk, he highlights the critical... parp inhibitor ovarian cancer optimizing therapy https://deliveryscience-appliedresearch.kaiserpermanente.org/publications/randomized-phase-ii-study-of-parp-inhibitor-veliparib-with-modified-folfiri-versus-folfiri-as-second-line-treatment-of-metastatic-pancreatic-cancer-swog-s1513/ Randomized Phase II Study of PARP Inhibitor Veliparib with Modified FOLFIRI versus FOLFIRI as... phase ii parp inhibitor study modified versus https://ctv.veeva.com/study/a-study-evaluating-talazoparib-bmn-673-a-parp-inhibitor-in-advanced-and-or-metastatic-breast-can A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast... The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus... a study parp inhibitor metastatic breast evaluating bmn https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1539880/full Frontiers | Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian... IntroductionClinical trials have shown that PARP inhibitors are effective in treating patients with platinum-sensitive ovarian cancer. They have been indicat... parp inhibitor frontiers poly adp ribose https://www.facingourrisk.org/research-clinical-trials/study/339/studying-the-effectiveness-of-new-parp-inhibitor-saruparib-compared-to-current-treatment-options-for-metastatic-prostate-cancer-evopar-pro1 Studying the Effectiveness of New PARP Inhibitor, Saruparib Compared to Current Treatment Options... This study will evaluate an investigational PARP inhibitor drug called Saruparib in combination with new hormonal agents in the treatment of metastatic... parp inhibitor treatment options studying effectiveness new https://breastcancernow.org/about-us/media/statements/we-respond-new-study-showing-how-some-cancer-cells-are-able-resist-parp-inhibitor-drugs A new study shows how some cancer cells are able to resist PARP inhibitor drugs | Breast Cancer Now Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, responded to a new study which shows how some cancer cells are able to... a new study cancer cells parp inhibitor shows able https://www.clinrol.com/study/161 PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours | Clinrol This study evaluates the safety of talazoparib with 177Lu-PRRT in patients with metastatic pancreatic or midgut neuroendocrine tumors. parp inhibitor neuroendocrine tumours dota patients https://www.knowcancer.com/cancer-trials/NCT00813956/ A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant... This study will investigate whether the neoadjuvant combination of gemcitabine, carboplatin, and BSI-201 will cause a high percentage of triple negative parp inhibitor phase study standard chemotherapy https://www.techtarget.com/pharmalifesciences/news/366607662/GSK-Gains-FDA-Approval-for-its-PARP-Inhibitor-Cancer-Treatment GSK Gains FDA Approval for its PARP Inhibitor Cancer Treatment | TechTarget GSK recently announced that FDA approved its PARP inhibitor cancer treatment for women with epithelial ovarian, fallopian tube, or peritoneal cancer. fda approval parp inhibitor cancer treatment gsk gains https://profiles.foxchase.org/en/publications/replication-gaps-are-a-key-determinant-of-parp-inhibitor-syntheti-2/ Correction: Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA... parp inhibitor synthetic lethality correction replication gaps https://www.rcsb.org/structure/6XVW RCSB PDB - 6XVW: Catalytic domain of human PARP-1 in complex with the inhibitor MC2050 Catalytic domain of human PARP-1 in complex with the inhibitor MC2050 rcsb pdb catalytic domain human parp https://massivebio.com/parp-1-inhibitor-abt-888-bio/ Parp 1 Inhibitor Abt 888 Dec 1, 2025 - Discover what Parp 1 Inhibitor Abt 888 is: an experimental compound scientists are investigating for its potential role in cancer therapy. parp inhibitor abt https://scholars.houstonmethodist.org/en/publications/histone-deacetylase-inhibitor-treatment-induces-brcaness-and-syne/ Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP... histone inhibitor treatment induces parp https://boa.unimib.it/handle/10281/506079 Distribution of pamiparib, a novel inhibitor of poly(ADP-ribose)-polymerase (PARP), in tumor tissue... a novel distribution inhibitor poly adp